Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease
Dry eye disease (DED) or keratoconjunctivitis sicca is a chronic multifactorial disorder of the ocular surface caused by tear film dysfunction. Symptoms include dryness, irritation, discomfort and visual disturbance, and standard treatment includes the use of lubricants and topical steroids. Seconda...
Main Authors: | Sangeeta Kumari, Madhuri Dandamudi, Sweta Rani, Elke Behaeghel, Gautam Behl, David Kent, Niall J. O’Reilly, Orla O’Donovan, Peter McLoughlin, Laurence Fitzhenry |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/6/905 |
Similar Items
-
Dry Eye Syndrome
by: Mohammad-Ali Javadi, et al.
Published: (2011-01-01) -
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
by: Paul Karpecki, et al.
Published: (2023-11-01) -
Ocular manifestation of rheumatoid arthritis-different forms and frequency
by: Gordana Zlatanović, et al.
Published: (2010-11-01) -
Prevalence of eye disease in Brazilian patients with psoriatic arthritis
by: Fernanda B. F. de Lima, et al.
Published: (2012-01-01) -
Chloroquine and Hydroxychloroquine in the Treatment of Dry Eye Disease
by: Julia Prinz, et al.
Published: (2023-06-01)